Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 167

1.

Mosapride improves food intake, while not worsening glycemic control and obesity, in ob/ob obese mice with decreased gastric emptying.

Asakawa A, Ueno N, Katagi M, Ijuin Y, Morita Y, Mizuno S, Inui T, Sakamaki R, Shinfuku N, Uemoto M.

J Diabetes Complications. 2006 Jan-Feb;20(1):56-8.

PMID:
16389169
2.

Urocortin reduces food intake and gastric emptying in lean and ob/ob obese mice.

Asakawa A, Inui A, Ueno N, Makino S, Fujino MA, Kasuga M.

Gastroenterology. 1999 Jun;116(6):1287-92.

PMID:
10348810
3.

Mosapride, a 5HT-4 receptor agonist, improves insulin sensitivity and glycaemic control in patients with Type II diabetes mellitus.

Ueno N, Inui A, Asakawa A, Takao F, Komatsu Y, Kotani K, Nishimura R, Kasuga M.

Diabetologia. 2002 Jun;45(6):792-7.

PMID:
12107722
4.

Pharmacological effects of the new gastroprokinetic agent mosapride citrate and its metabolites in experimental animals.

Yoshida N, Omoya H, Kato S, Ito T.

Arzneimittelforschung. 1993 Oct;43(10):1078-83.

PMID:
8267674
5.

Effect of mosapride on glycemic control and gastric emptying in type 2 diabetes mellitus patients with gastropathy.

Asakawa H, Hayashi I, Fukui T, Tokunaga K.

Diabetes Res Clin Pract. 2003 Sep;61(3):175-82.

PMID:
12965107
6.

Effects of mosapride citrate, metoclopramide hydrochloride, lidocaine hydrochloride, and cisapride citrate on equine gastric emptying, small intestinal and caecal motility.

Okamura K, Sasaki N, Yamada M, Yamada H, Inokuma H.

Res Vet Sci. 2009 Apr;86(2):302-8. doi: 10.1016/j.rvsc.2008.07.008.

PMID:
18723200
7.

The effect of mosapride citrate on constipation in patients with diabetes.

Ueno N, Inui A, Satoh Y.

Diabetes Res Clin Pract. 2010 Jan;87(1):27-32. doi: 10.1016/j.diabres.2009.09.024.

PMID:
19889470
8.

The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying.

Futagami S, Iwakiri K, Shindo T, Kawagoe T, Horie A, Shimpuku M, Tanaka Y, Kawami N, Gudis K, Sakamoto C.

J Gastroenterol. 2010 Apr;45(4):413-21. doi: 10.1007/s00535-009-0173-0.

PMID:
19997942
11.

Effects of gastroprokinetic agents on gastroparesis in streptozotocin-induced diabetic rats.

Yamano M, Kamato T, Nagakura Y, Miyata K.

Naunyn Schmiedebergs Arch Pharmacol. 1997 Jul;356(1):145-50.

PMID:
9228202
12.

Influence of mosapride citrate on gastric motility and autonomic nervous function: evaluation by spectral analyses of heart rate and blood pressure variabilities, and by electrogastrography.

Endo J, Nomura M, Morishita S, Uemura N, Inoue S, Kishi S, Kawaguchi R, Iga A, Ito S, Nakaya Y.

J Gastroenterol. 2002;37(11):888-95.

PMID:
12483243
13.

[D-LEU-4]-OB3, a synthetic leptin agonist, improves hyperglycemic control in C57BL/6J ob/ob mice.

Grasso P, Rozhavskaya-Arena M, Leinung MC, Lee DW.

Regul Pept. 2001 Sep 15;101(1-3):123-9.

PMID:
11495687
14.

Effects of mitemcinal (GM-611), an orally active erythromycin-derived prokinetic agent, on delayed gastric emptying and postprandial glucose in a new minipig model of diabetes.

Ozaki K, Monnai M, Onoma M, Muramatsu H, Yogo K, Watanabe T, Oda Y, Katagiri K, Arakawa H, Itoh Z, Omura S, Takanashi H.

J Diabetes Complications. 2008 Sep-Oct;22(5):339-47. doi: 10.1016/j.jdiacomp.2007.03.005.

PMID:
18413164
15.

The prokinetic effect of mosapride citrate on horse gastric emptying rates.

Okamura K, Sasaki N, Fukunaka M, Yamada H, Inokuma H.

J Vet Med Sci. 2008 Jun;70(6):627-8.

16.
19.
20.

Effects of cyclo (his-pro) plus zinc on glucose metabolism in genetically diabetic obese mice.

Hwang IK, Go VL, Harris DM, Yip I, Kang KW, Song MK.

Diabetes Obes Metab. 2003 Sep;5(5):317-24.

PMID:
12940869
Items per page

Supplemental Content

Support Center